Piper Sandler analyst Edward Tenthoff reiterates Sutro Biopharma (NASDAQ:STRO) with a Overweight and lowers the price target...

Oppenheimer analyst Jay Olson maintains Sutro Biopharma (NASDAQ:STRO) with a Outperform and maintains $10 price target.

Truist Securities analyst Asthika Goonewardene maintains Sutro Biopharma (NASDAQ:STRO) with a Buy and lowers the price targe...

JMP Securities analyst Reni Benjamin reiterates Sutro Biopharma (NASDAQ:STRO) with a Market Outperform and maintains $17 pri...

Sutro Biopharma shares are trading lower by 4.3% during Tuesday's session. The company announced the pricing of an underwri...

Ipsen secures exclusive global rights for development and commercialization of STRO-003, an antibody-drug conjugate, completi...

Shares of Kodiak Sciences Inc. (NASDAQ: KOD) fell sharply during Thursday’s session after the company reported a wider-than-e...

U.S. stocks were slightly higher, with the S&P 500 gaining around 0.1% on Thursday. Shares of REX American Resources Corpo...